[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D.Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
[3] Yang JD, Hainaut P, Gores GJ, et al.A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[4] 曾勇,谢坤林. 肝癌全程管理模式[J]. 中国实用外科杂志,2021,41(3):343-347.
[5] Wen Y, Han J, Chen J.Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma[J]. Int J Cancer, 2015, 137(7): 1679-1690.
[6] Yin T, Zhao H. miR-152-3p impedes the malignant phenotypes of hepatocellular carcinoma by repressing roundabout guidance receptor 1[J]. Cell Mol Biol Lett, 2022, 27(1): 22.
[7] 时晓晓,董翔,于若卉. miR-203a-3p靶向GLS1调控HCC细胞增殖、迁移、侵袭的机制研究[J]. 现代检验医学杂志,2022,37(5):86-92,122.
[8] Song JL, Nigam P, Tektas SS, et al.microRNA regulation of Wnt signaling pathways in development and disease[J]. Cell Signal, 2015, 27(7): 1380-1391.
[9] Thapar R, Denmon AP.Signaling pathways that control mRNA turnover[J]. Cell Signal, 2013, 25(8): 1699-1710.
[10] Hussen BM, Hidayat HJ, Salihi A, et al.MicroRNA: A signature for cancer progression[J]. Biomed Pharmacother, 2021, 138: 111528.
[11] Nusse R, Clevers H.Wnt/β-Catenin Signaling Disease and Emerging Therapeutic Modalities[J]. Cell, 2017, 169(6): 985-999.
[12] 嘉红云,黄思聪,陈浩宇,等. miR-106b在肝癌细胞中激活Wnt通路[J]. 实用医学杂志,2015,(19):3140-3142.
[13] 从美丽,马依热·努尔买卖提,周蓓,等. 甘草酸介导miRNAs对大鼠酒精性肝损伤的保护作用[J]. 安徽医科大学学报,2023,58(8):1374-1379.
[14] Roy S, Sunkara RR, Parmar MY, et al.EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential[J]. Front Biosci (Landmark Ed), 2021, 26(2): 238-265.
[15] Sugawara Y, Hibi T.Surgical treatment of hepatocellular carcinoma[J]. Biosci Trends, 2021, 15(3): 138-141.
[16] Liu D, Song T.Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China[J]. Biosci Trends, 2021, 15(3): 142-147.
[17] 孙家跃,左靖,金义光. 吉西他滨的体内外抗肝癌作用研究[J]. 中国药房,2015,(28):3941-3943.
[18] Pai SG, Carneiro BA, Mota JM, et al.Wnt/beta-catenin pathway: modulating anticancer immune response[J]. Hematol Oncol, 2017, 10(1): 101.
[19] Liu Y, El-Serag HB, Jiao L.WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients[J]. PLoS One, 2013, 8(12): e84407.
[20] 朱金霞,刘光伟,杨培伟. 中医药调控Wnt/β-catenin通路治疗肝细胞癌的研究进展[J]. 中国中医基础医学杂志,2023,29(4):679-686.
[21] Harb J, Lin PJ, Hao J.Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics[J]. Curr Oncol Rep, 2019, 21(2): 12.
[22] 张志红,朱真如,盛海龙,等. TRIM21可抑制肝癌细胞的侵袭能力:基于泛素化途径降解β-catenin[J]. 南方医科大学学报,2022,42(1):55-62.
[23] 李武兵,王烯冬,马耀宏,等. miR-152-5p对肝癌细胞恶性生物学行为的抑制作用及其机制[J]. 山西医科大学学报,2022,53(10):1219-1226.
[24] Liu LJ, Xie SX, Chen YT, et al.Aberrant regulation of Wnt signaling in hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22(33): 7486-7499.
[25] Russell JO, Monga SP.Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology[J]. Annu Rev Pathol, 2018, 13: 351-378.
[26] Galle PR, Dufour JF, Peck-Radosavljevic M, et al.Systemic therapy of advanced hepatocellular carcinoma[J]. Future Oncol, 2021, 17(10): 1237-1251.
[27] 石永杰,陈旖鹛,黄思聪. SRPK1激活Wnt/β-catenin通路促进肝癌细胞上皮间充质转化[J]. 西部医学,2023,35(7):951-958.
[28] Yin T, Liu MM, Jin RT, et al.miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8[J]. Pathol Res Pract, 2019, 215(6): 152406.
[29] Li Z, Wu L, Tan W, et al.MiR-20b-5p promotes hepatocellular carcinoma cell proliferation, migration and invasion by down-regulating CPEB3[J]. Ann Hepatol, 2021, 23: 100345.
[30] Zhao G, Wang T, Huang QK, et al.MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737[J]. World J Gastroenterol, 2016, 22(23): 5364-5373. |
